Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 12, 2026Polskie Archiwum Medycyny WewnętrznejOpen Access

Direct oral anticoagulants in older patients with atrial fibrillation and comorbidities: frailty, renal impairment, acute or chronic coronary syndromes, and acute stroke

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do direct oral anticoagulants improve stroke prevention and reduce bleeding compared to vitamin K antagonists or other therapies in older patients with atrial fibrillation and complex comorbidities?

Population

Older patients with atrial fibrillation and comorbidities including frailty, renal impairment, acute or…

Comparison

Direct oral anticoagulants including apixaban… vs Vitamin K antagonists, antiplatelet therapy, or…

Design

Review

Authors

FAFelicita AndreottiABAdhithya N. BalajiLCLuigi Cappannoli

Discussion

Loading...

Member takes

Overview

Requires vigilant renal monitoring for DOAC use in elderly AF; leaves open optimal strategies in severe impairment.

Key Points

  • This research aims to evaluate the safety and effectiveness of direct oral anticoagulants in older patients with atrial fibrillation and various comorbidities.
  • Analysis of pivotal trials comparing direct oral anticoagulants to warfarin in atrial fibrillation patients.
  • Examination of renal function impact on direct oral anticoagulant dosing.
  • Assessment of bleeding risks and management strategies in patients with acute coronary syndromes and ischemic strokes.
  • DOACs demonstrate overall advantages over warfarin in older, frail patients, reducing major bleeding incidents.
  • AF patients with a creatinine clearance <30mL/min face significant risks; specific DOACs are contraindicated.
  • Recent exposure to DOACs is a relative contraindication for thrombolysis in acute ischemic stroke cases.

Structured PICO

Do direct oral anticoagulants improve stroke prevention and reduce bleeding compared to vitamin K antagonists or other therapies in older patients with atrial fibrillation and complex comorbidities?

P
Population
Older patients with atrial fibrillation and comorbidities including frailty, renal impairment, acute or chronic coronary syndromes, and acute stroke
I
Intervention
Direct oral anticoagulants (DOACs) including apixaban, dabigatran, edoxaban, and rivaroxaban, with dose adjustments based on renal function and age
C
Comparator
Vitamin K antagonists (warfarin), antiplatelet therapy, or no anticoagulation, depending on the specific clinical scenario
O
Outcome
Prevention of stroke and systemic embolism, and risk of major bleeding (including intracranial hemorrhage)

Advanced age and complex comorbidities should not exclude DOAC use in AF patients, provided doses are appropriately adjusted for renal function and bleeding mitigation strategies are employed.

Limitations

  • Significant gaps in evidence are present for multimorbid patients
  • Need for geriatric-focused clinical trials

Cite This Study

Andreotti et al. (2026) studied this question.

synapsesocial.com/papers/6a2bd1386550ea4541ffe990https://doi.org/10.20452/pamw.17319
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Consider frailty status and comorbidities when choosing anticoagulant treatment for older patients with atrial fibrillation2026
  2. 2Clinical Outcomes of Oral Anticoagulation in Elderly East Asian Patients with Atrial Fibrillation: A Retrospective Single-Center Study2025
  3. 3Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk2026 · 1 citations
  4. 4Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation.2026
  5. 5Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality2026